For Healthcare Professionals

SYLVANT® is the only FDA-approved therapy for the treatment of patients with Multicentric Castleman’s Disease who are HIV negative and HHV-8 negative

SYLVANT® (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with Multicentric Castleman’s Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.1

Limitation of use: SYLVANT® was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT® did not bind to virally produced IL-6 in a nonclinical study.1

CONTRAINDICATIONS

Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT®.

Reference

1. SYLVANT® [package insert]. Horsham, PA: Janssen Biotech, Inc.

Please click here to see full Prescribing Information.